A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours

被引：0
|
作者：
Hyung-Don Kim
Changhoon Yoo
Min-Hee Ryu
Yoon-Koo Kang
机构：
[1] University of Ulsan College of Medicine,Department of Oncology, Asan Medical Center
来源：
British Journal of Cancer | 2023年 / 129卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：275 / 282
页数：7
相关论文
共 50 条
  • [1] A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
    Kim, Hyung-Don
    Yoo, Changhoon
    Ryu, Min-Hee
    Kang, Yoon-Koo
    BRITISH JOURNAL OF CANCER, 2023, 129 (02) : 275 - 282
  • [2] A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
    Kim, Hyung-Don
    Yoo, Changhoon
    Ryu, Min-Hee
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors
    Yoo, C.
    Ryu, M. -H.
    Na, Y. S.
    Ryoo, B. -Y.
    Park, S. R.
    Kang, Y. -K.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2272 - 2277
  • [4] Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
    Serrano, Cesar
    Leal, Alessandro
    Kuang, Yanan
    Morgan, Jeffrey A.
    Barysauskas, Constance M.
    Phallen, Jillian
    Triplett, Olivia
    Marino-Enriquez, Adrian
    Wagner, Andrew J.
    Demetri, George D.
    Velculescu, Victor E.
    Paweletz, Cloud P.
    Fletcher, Jonathan A.
    George, Suzanne
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7287 - 7293
  • [5] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours.
    Agus, D. B.
    Terlizzi, E.
    Stopfer, P.
    Amelsberg, A.
    Gordon, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 97S - 97S
  • [6] A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
    Das, Millie
    Padda, Sukhmani K.
    Frymoyer, Adam
    Molina, Julian
    Adjei, Alex
    Lensing, Janet L.
    Miles, Dale
    Sikic, Branimir I.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) : 541 - 550
  • [7] A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
    Millie Das
    Sukhmani K. Padda
    Adam Frymoyer
    Julian Molina
    Alex Adjei
    Janet L. Lensing
    Dale Miles
    Branimir I. Sikic
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 541 - 550
  • [8] A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
    Ciara M. Kelly
    Alexander N. Shoushtari
    Li-Xuan Qin
    Sandra P. D’Angelo
    Mark A. Dickson
    Mrinal M. Gounder
    Mary Louise Keohan
    Chloe Mcfadyen
    Ana Sjoberg
    Samuel Singer
    Ronald P. DeMatteo
    Sinchun Hwang
    M. H. Heinemann
    Jasmine H. Francis
    Cristina R. Antonescu
    Ping Chi
    William D. Tap
    Investigational New Drugs, 2019, 37 : 282 - 290
  • [9] A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
    Kelly, Ciara M.
    Shoushtari, Alexander N.
    Qin, Li-Xuan
    D'Angelo, Sandra P.
    Dickson, Mark A.
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Mcfadyen, Chloe
    Sjoberg, Ana
    Singer, Samuel
    DeMatteo, Ronald P.
    Hwang, Sinchun
    Heinemann, M. H.
    Francis, Jasmine H.
    Antonescu, Cristina R.
    Chi, Ping
    Tap, William D.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 282 - 290
  • [10] Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
    Hans Gelderblom
    Robin L. Jones
    Suzanne George
    Claudia Valverde Morales
    Charlotte Benson
    Daniel J. Jean-Yves Blay
    Toshihiko Renouf
    Axel Doi
    Michael Le Cesne
    Sabine Leahy
    Paola Hertle
    Ulrike Aimone
    Patrick Brandt
    British Journal of Cancer, 2020, 122 : 1158 - 1165
12345